HomepageTWST • NASDAQ
add
Twist Bioscience Corp
Vorige slotkoers
$Â 32,61
Dag-range
$Â 30,72 - $Â 33,59
Jaar-range
$Â 30,72 - $Â 60,90
Beurswaarde
1,85Â mld. USD
Gem. volume
1,30Â mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 92,79Â mln. | 23,23% |
Bedrijfskosten | 87,59Â mln. | 9,80% |
Netto inkomsten | -39,33Â mln. | 13,55% |
Netto winstmarge | -42,38 | 29,85% |
Winst per aandeel | -0,66 | 16,46% |
EBITDA | -35,16Â mln. | 13,38% |
Effectief belastingtarief | -0,45% | — |
Balans
Totale activa
Totale passiva
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 257,15Â mln. | -12,34% |
Totale activa | 595,62Â mln. | -15,26% |
Totale passiva | 155,51Â mln. | 8,96% |
Totaal aandelenvermogen | 440,11 mln. | — |
Uitstaande aandelen | 59,92 mln. | — |
Koers-boekwaardeverhouding | 4,44 | — |
Rendement op activa | -17,26% | — |
Rendement op kapitaal | -19,62% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -39,33Â mln. | 13,55% |
Operationele kasstroom | -12,99Â mln. | 33,14% |
Kasstroom uit beleggingen | -1,43Â mln. | 72,79% |
Kasstroom uit financiering | 3,20Â mln. | 74,84% |
Nettomutatie in liquide middelen | -11,11Â mln. | 51,48% |
Vrije kasstroom | -5,15Â mln. | 14,52% |
Over
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Opgericht
2013
Website
Werknemers
923
